Fine chemical

XinKailian Biotechnology Unveils GMP-Certified Ubiquinol with Patent Safety, Set for Debut at Vitafoods Asia 2024

Retrieved on: 
Sunday, September 15, 2024
S10, Yili, Law, Good manufacturing practice, Intellectual property, Absorption, Kilpatrick Townsend & Stockton, Temperature, Coenzyme Q10, Freedom, Patent, Risk, Biotechnology, GMP, Fine chemical

It will make its first public appearance at Vitafoods Asia 2024.

Key Points: 
  • It will make its first public appearance at Vitafoods Asia 2024.
  • Amid growing market concerns over potential patent infringement lawsuits, XinKailian Biotechnology has conducted a thorough FTO analysis.
  • XinKailian Biotechnology is equipped to meet global demand with fully operational facilities adhering to Good Manufacturing Practices (GMP).
  • XinKailian Biotechnology will be showcasing its new GMP-certified Ubiquinol at Vitafoods Asia 2024, from September 18-20 at the Queen Sirikit National Convention Center in Bangkok.

Impetus Wellness Group Announces Launch of VMS Platform and Partnership with Reliance Vitamin

Retrieved on: 
Friday, September 13, 2024
BK, AEA Investors, Growth, Mineral, Organization, Health, UNFI, Platform, Vitamin, Leiner Health Products, CMOS, Small business, VMS, Partnership, CMO, CPG, Fine chemical

EDISON, N.J., Sept. 13, 2024 /PRNewswire/ -- Impetus Wellness Group ("Impetus" or the "Platform") today announced the launch of its platform through a partnership with Reliance Vitamin ("Reliance").

Key Points: 
  • EDISON, N.J., Sept. 13, 2024 /PRNewswire/ -- Impetus Wellness Group ("Impetus" or the "Platform") today announced the launch of its platform through a partnership with Reliance Vitamin ("Reliance").
  • Impetus is a wellness-focused platform dedicated to fostering the leadership and growth of companies in the vitamins, minerals, and supplements ("VMS") space.
  • "We are thrilled to launch the Impetus platform with Reliance Vitamin," said Ben Althaus, Partner on the AEA SBPE team.
  • Impetus Wellness Group plans to continue its expansion by partnering with additional VMS CMOs, positioning itself as a leader in the evolving health and wellness industry.

Avance Clinical Joins the Australian Clinical Trials Roadshow, Sharing Cost and Time Benefits for Early-Phase US Biotechs

Retrieved on: 
Friday, September 13, 2024
EMA, Drug development, Clinical trial, FDA, Environment, Toy, Conference, Ecosystem, Technology Square, ChromeOS, Lodge, WAKE, IND, Lighthouse Café, Convention center, CNS, Fine chemical

Key Avance Clinical Australia benefits include:

Key Points: 
  • Key Avance Clinical Australia benefits include:
    Australian studies do not require an IND which means rapid startup.
  • An incentive rebate of 43.5% on clinical trial spend from the Australia Government, for eligible companies, making the dollar go further.
  • Toy said biotechs will come away with a complete and first-hand understanding of the world-class clinical practices that make Australia a premier destination for clinical trials.
  • “Avance Clinical is a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs,” said Toy.

EVI Industries Reports Fourth Quarter and Fiscal Year Results, Including Record $33M in Operating Cash Flows

Retrieved on: 
Thursday, September 12, 2024
Consulting, Machinery, Professional Services, Manufacturing, Investment, Tax, GAAP, Security (finance), Growth, Knowledge, Exercise, Acquisition, OEM, Family, Compensation, Interest, EVI, Fine chemical

EVI Industries, Inc. (NYSE American: EVI) announced its operating results for the three- and twelve-month periods ended June 30, 2024, including record gross profit, record gross margin, and record operating cash flows for fiscal 2024, and record gross margin and record operating cash flows for the three-month period ended June 30, 2024.

Key Points: 
  • EVI Industries, Inc. (NYSE American: EVI) announced its operating results for the three- and twelve-month periods ended June 30, 2024, including record gross profit, record gross margin, and record operating cash flows for fiscal 2024, and record gross margin and record operating cash flows for the three-month period ended June 30, 2024.
  • The three-year compounded annual revenue growth rate for businesses the Company has owned for at least four years is 8.0%.
  • During fiscal 2024, the Company set another fiscal year record for gross profit at $105 million and another fiscal year record for gross margin at 30%.
  • During fiscal 2024, the Company generated a record $33 million in operating cash flow, a $32 million increase over prior year, and a record $12 million in operating cash flow during the fourth quarter of fiscal 2024, a $4.8 million increase compared to the same period of the prior fiscal year.

Europe Automated Sample Preparation Market for Genomic Applications - Analysis and 10 Year Forecast 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 12, 2024
Health, General Health, Growth, Laboratory, Genomics, Human, Automation, Investment, Research, Proteomics, Country, Fine chemical

The "Europe Automated Sample Preparation Market (For Genomic Applications): Focus on Product, Application, End-User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Automated Sample Preparation Market (For Genomic Applications): Focus on Product, Application, End-User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the automated sample preparation market in Europe is fueled by the rising demand for high-throughput and standardized sample processing, particularly in industries like genomics.
  • As research and diagnostic needs evolve, laboratories increasingly adopt automated sample preparation solutions to optimize and streamline their analytical workflows.
  • Competitive Strategy: The Europe automated sample preparation market is a highly fragmented market, with many smaller and private companies constantly entering the market.

SSON Research & Analytics Unveils 2024 Top 20 Most Admired Shared Services Organizations & Global Business Services

Retrieved on: 
Thursday, September 12, 2024
Research, IBM Consulting, Travel, Talent management, Faculty, Benchmarking, Organization, SSO, GBS, HR, Payroll, Shared services, OneSource, Fine chemical

NEW YORK, Sept. 12, 2024 /PRNewswire-PRWeb/ -- SSON Research & Analytics, the global data analytics center of the Shared Services & Outsourcing Network (SSON), has announced the 2024 list of the Top 20 Most Admired Shared Services Organizations (SSOs) and Global Business Services (GBS).

Key Points: 
  • NEW YORK, Sept. 12, 2024 /PRNewswire-PRWeb/ -- SSON Research & Analytics, the global data analytics center of the Shared Services & Outsourcing Network (SSON), has announced the 2024 list of the Top 20 Most Admired Shared Services Organizations (SSOs) and Global Business Services (GBS).
  • "In celebrating the 2024 Top 20 Most Admired Shared Services Organizations and Global Business Services, we recognize the exceptional leaders who are setting new standards of excellence in the industry.
  • Noteworthy Newcomers: This year's list welcomes new entrants such as Allianz Services, ArcelorMittal Business Center of Excellence, Cencosud Shared Service Center, Estee Lauder Companies - OneSource, Henkel Global Business Solutions+, Holcim ABS, Merck - GBS Finance, Nokia Business Services, and Novo Nordisk Global Business Services.
  • SSON Research & Analytics will be presenting a webinar on October 22nd showcasing the outstanding results of the Top 20 winners.

Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform

Retrieved on: 
Thursday, September 12, 2024
Flow cytometry, Environment, Stem cell, Automation, Sony, CDMO, HSC, Cell, ISO, SAN, Fine chemical

Cellares and Sony will collaborate on integrating Sony's cell sorting and analytical technologies into the Cell Shuttle, Cellares' automated cell therapy manufacturing platform

Key Points: 
  • Cellares and Sony will collaborate on integrating Sony's cell sorting and analytical technologies into the Cell Shuttle, Cellares' automated cell therapy manufacturing platform
    Additionally, this integration will allow for real-time monitoring of cell quality and quantity, which is expected to enhance the efficiency and scalability of cell therapy manufacturing on the Cell Shuttle
    SOUTH SAN FRANCISCO, Calif. and TOKYO, Sept. 12, 2024 /PRNewswire/ -- Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO) and a leader in automated cell therapy manufacturing, and Sony Corporation ("Sony"), a technology pioneer driving innovation in the field of flow cytometry, today announced a collaboration to jointly develop and integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle™, an automated cell therapy manufacturing platform.
  • The combination of the two industry-leading technologies is expected to make Cellares' Cell Shuttle the world's first truly automated, end-to-end cell therapy manufacturing solution with cell analysis and sorting capabilities.
  • Cellares' Cell Shuttle is an automated, scalable, and integrated manufacturing platform that represents a leap forward in cell therapy manufacturing.
  • Designed to meet the rigorous demands of clinical and commercial-scale manufacturing, the Cell Shuttle automates and integrates all cell therapy manufacturing unit operations within a closed, ISO 8 environment.

Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform

Retrieved on: 
Thursday, September 12, 2024
Health, Technology, Health Technology, Software, Pharmaceutical, Hardware, Biotechnology, Flow cytometry, Environment, Stem cell, Automation, Sony, CDMO, HSC, Cell, ISO, Fine chemical

Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) and a leader in automated cell therapy manufacturing, and Sony Corporation ("Sony"), a technology pioneer driving innovation in the field of flow cytometry, today announced a collaboration to jointly develop and integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle™, an automated cell therapy manufacturing platform.

Key Points: 
  • Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) and a leader in automated cell therapy manufacturing, and Sony Corporation ("Sony"), a technology pioneer driving innovation in the field of flow cytometry, today announced a collaboration to jointly develop and integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle™, an automated cell therapy manufacturing platform.
  • The combination of the two industry-leading technologies is expected to make Cellares’ Cell Shuttle the world’s first truly automated, end-to-end cell therapy manufacturing solution with cell analysis and sorting capabilities.
  • Cellares’ Cell Shuttle is an automated, scalable, and integrated manufacturing platform that represents a leap forward in cell therapy manufacturing.
  • Designed to meet the rigorous demands of clinical and commercial-scale manufacturing, the Cell Shuttle automates and integrates all cell therapy manufacturing unit operations within a closed, ISO 8 environment.

Circe Announces $5M Seed Round and Pilot Plant

Retrieved on: 
Thursday, September 12, 2024
Engineering, Polymer, ARPA, Food, Oil, Harvard University, Sugar, Fermentation, Cosmetics, Animal, Fats, Plant, Nature, Biofuel, Wyss Institute, Biodiversity loss, Parity, Biology, Carbon, Protein, CO2, Fine chemical

Boston, MA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Circe , a carbon-negative manufacturing company, announced today a $5M Seed Round.

Key Points: 
  • Boston, MA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Circe , a carbon-negative manufacturing company, announced today a $5M Seed Round.
  • Investors in this round include ReGen Ventures, Undeterred Capital, Ponderosa Ventures, Bee Partners, Exceptional Ventures, Climate Capital, and Safar Partners.
  • In addition to its funding round, Circe also announced the installation of its pilot plant in Waltham, MA.
  • With the operation of the plant, Circe will be able to move out of the lab where it demonstrated proof of concept and begin producing carbon-negative molecules at the next scale.

Modine Updates Multi-Year Strategy at Investor Day

Retrieved on: 
Wednesday, September 11, 2024
Development, Outline, Fine chemical

RACINE, Wis., Sept. 11, 2024 /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, today hosted an Investor Day at its global headquarters in Racine, Wisconsin. Members of the executive management team provided an update to the company's strategy to transform the company and drive sustainable shareholder value. Guided by the company's ongoing commitment to 80/20, management outlined its strategy to evolve its portfolio to compound shareholder value by focusing on high-growth, high-margin businesses for sustainable growth and returns. 

Key Points: 
  • RACINE, Wis., Sept. 11, 2024 /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, today hosted an Investor Day at its global headquarters in Racine, Wisconsin.
  • Members of the executive management team provided an update to the company's strategy to transform the company and drive sustainable shareholder value.
  • Guided by the company's ongoing commitment to 80/20, management outlined its strategy to evolve its portfolio to compound shareholder value by focusing on high-growth, high-margin businesses for sustainable growth and returns.
  • "The deliberate actions we have taken to reposition Modine for a brighter future are working, as we significantly outperformed the financial goals we set during our initial Investor Day in June 2022.